29 April 2021 in Frontiers in Immunology
MKMariola Kurowska-Stolarska
Mariola Kurowska-Stolarska
Mitochondria are major energy-producing organelles that have central roles in cellular metabolism. They also act as important signalling hubs, and their dynamic regulation in response to stress signals helps to dictate the stress response of the cell. Rheumatoid arthritis is an inflammatory and autoimmune disease with high prevalence and complex aetiology. Mitochondrial activity affects differentiation, activation and survival of immune and non-immune cells that contribute to the pathogenesis of this disease. This review outlines what is known about the role of mitochondria in rheumatoid arthritis pathogenesis, and how current and future therapeutic strategies can function through modulation of mitochondrial activity. We also highlight areas of this topic that warrant further study. As producers of energy and of metabolites such as succinate and citrate, mitochondria help to shape the inflammatory phenotype of leukocytes during disease. Mitochondrial components can directly stimulate immune receptors by acting as damage-associated molecular patterns, which could represent an initiating factor for the development of sterile inflammation. Mitochondria are also an important source of intracellular reactive oxygen species, and facilitate the activation of the NLRP3 inflammasome, which produces cytokines linked to disease symptoms in rheumatoid arthritis. The fact that mitochondria contain their own genetic material renders them susceptible to mutation, which can propagate their dysfunction and immunostimulatory potential. Several drugs currently used for the treatment of rheumatoid arthritis regulate mitochondrial function either directly or indirectly. These actions contribute to their immunomodulatory functions, but can also lead to adverse effects. Metabolic and mitochondrial pathways are attractive targets for future anti-rheumatic drugs, however many questions still remain about the precise role of mitochondrial activity in different cell types in rheumatoid arthritis.
10 December 2021 in Science Advances
Exchange of mitochondrial subunits C15ORF48 and NDUFA4 occurs during macrophage activation in vitro and in inflammatory disease.
1 January 2023 in Discovery Immunology
Synthetic glucocorticoids are used to treat many chronic and acute inflammatory conditions. Frequent adverse effects of prolonged exposure to glucocorticoids include disturbances of glucose homeostasis caused by changes in glucose traffic and metabolism in muscle, liver, and adipose tissues. Macrophages are important targets for the anti-inflammatory actions of glucocorticoids. These cells rely on aerobic glycolysis to support various pro-inflammatory and antimicrobial functions. Employing a potent pro-inflammatory stimulus in two commonly used model systems (mouse bone marrow-derived and human monocyte-derived macrophages), we showed that the synthetic glucocorticoid dexamethasone inhibited lipopolysaccharide-mediated activation of the hypoxia-inducible transcription factor HIF-1α, a critical driver of glycolysis. In both cell types, dexamethasone-mediated inhibition of HIF-1α reduced the expression of the glucose transporter GLUT1, which imports glucose to fuel aerobic glycolysis. Aside from this conserved response, other metabolic effects of lipopolysaccharide and dexamethasone differed between human and mouse macrophages. These findings suggest that glucocorticoids exert anti-inflammatory effects by impairing HIF-1α-dependent glucose uptake in activated macrophages. Furthermore, harmful and beneficial (anti-inflammatory) effects of glucocorticoids may have a shared mechanistic basis, depending on the alteration of glucose utilization.
21 September 2025 in bioRxiv
The oxygen-sensitive transcription factor HIF-1α (hypoxia-inducible factor 1α) is a master regulator of cellular and organism-level adaptations to decreasing oxygen availability. Under conditions of oxygen sufficiency HIF-1α is constitutively produced and degraded. In response to hypoxia, the degradation pathway is inhibited and HIF-1α protein accumulates via mechanisms that are now well understood. Additional signals combine with the oxygen-sensitive protein degradation pathway to modulate the expression and/or activity of HIF-1α. In the context of the immune system, HIF-1α can be activated under normoxic conditions by a variety of stimuli, including the pro-inflammatory agonist lipopolysaccharide. Here we use a variety of genetic and pharmacological approaches to reveal that lipopolysaccharide-induced HIF-1α accumulation in primary macrophages is dependent on mitogen-activated protein kinase p38. This response is not dependent on modulation of HIF-1α protein stability: instead, it involves the phosphorylation and inactivation of tristetraprolin, an mRNA destabilizing protein that targets Hif1a mRNA for degradation. We previously reported that the glucocorticoid dexamethasone inhibits lipopolysaccharide-induced HIF-1α accumulation and metabolic reprograming in primary macrophages. Here we tested and disproved the hypothesis that dexamethasone prevents HIF-1α accumulation by inducing expression of dual specificity phosphatase 1 and thereby inhibiting p38 function. Hence two novel mechanisms critically regulate HIF-1α activation in lipopolysaccharide-treated macrophages: a p38-dependent mechanism that operates at the post-transcriptional level to control Hif1a mRNA expression, and a glucocorticoid-sensitive mechanism that operates at the post-translational level to control HIF-1α protein stability. Combined targeting of these two mechanisms may exert therapeutic effects in contexts where HIF-1α contributes to immune-mediated inflammatory pathology.
22 September 2023 in bioRxiv
Synthetic glucocorticoids are used to treat many chronic and acute inflammatory conditions. Frequent adverse effects of prolonged exposure to glucocorticoids include disturbances of glucose homeostasis, caused by changes of glucose traffic and metabolism in muscle, liver and adipose tissues. Macrophages are important targets for the anti-inflammatory actions of glucocorticoids. These cells rely on aerobic glycolysis to support various pro-inflammatory and antimicrobial functions. Employing a potent pro-inflammatory stimulus in two commonly-used model systems (mouse bone marrow-derived and human monocyte-derived macrophages), we showed that the synthetic glucocorticoid dexamethasone inhibited lipopolysaccharide-mediated activation of the hypoxia- inducible transcription factor HIF-1α, a critical driver of glycolysis. In both cell types, dexamethasone-mediated inhibition of HIF-1α reduced the expression of the glucose transporter GLUT1, which imports glucose to fuel aerobic glycolysis. Aside from this conserved response, other metabolic effects of lipopolysaccharide and dexamethasone differed between human and mouse macrophages. These findings suggest that glucocorticoids exert anti-inflammatory effects by impairing HIF-1α-dependent glucose uptake in activated macrophages. Furthermore, harmful and beneficial (anti-inflammatory) effects of glucocorticoids may have a shared mechanistic basis, depending on alteration of glucose utilisation. GRAPHICAL
24 December 2025 in Journal of Biological Chemistry
In macrophages, the hypoxia-inducible transcription factor 1α (HIF-1α) can be activated under normoxic conditions by proinflammatory agonists such as lipopolysaccharide (LPS). This noncanonical HIF-1α activation allows macrophages to accommodate rapidly changing demands for energy and biosynthetic precursors in the face of an immune challenge. Alterations in HIF-1α hydroxylation and proteolysis have been implicated in the response, but the involvement of other signaling mechanisms and pathways is unclear. Here, we use genetic and pharmacological approaches to show that LPS-induced HIF-1α accumulation in primary macrophages is dependent on mitogen-activated protein kinase p38 and mediated by the phosphorylation and inactivation of tristetraprolin, an mRNA destabilizing protein that targets Hif1a mRNA for degradation. We previously reported that the glucocorticoid dexamethasone inhibits LPS-induced HIF-1α accumulation and metabolic reprogramming in primary macrophages. Here, we tested and disproved the hypothesis that dexamethasone exerts this effect via the mitogen-activated protein kinase p38 inactivator dual specificity phosphatase 1. Hence, two novel mechanisms critically regulate HIF-1α activation in LPS-treated macrophages: a p38-dependent mechanism that operates at the post-transcriptional level to control Hif1a mRNA stability, and a glucocorticoid-sensitive mechanism that operates at the post-translational level to control HIF-1α protein stability. Combined targeting of these two mechanisms may exert therapeutic effects in contexts where HIF-1α contributes to immune-mediated inflammatory pathology.